According to Market.us, the global market size for alpha-1 antitrypsin deficiency augmentation therapy is projected to reach approximately USD 2,517 million by 2032, up from USD 1,413 million in 2022.

According to Market.us, the global alpha-1 antitrypsin deficiency augmentation therapy market growth is driven by the increase in the prevalence of Genetic and Respiratory diseases and modern ...

The global alpha-1 antitrypsin deficiency (AATD) augmentation therapy market is projected to reach USD 2,517 million by 2032, up from USD 1,413 million in 2022, growing at a CAGR of 6.1% during the ...

Prime Medicine, Inc. achieved strong early data in CGD with PM359, surpassing efficacy thresholds. Click here to find out why ...

Second generation gene therapy for alpha 1-antitrypsin deficiency Peer-Reviewed Publication. Mary Ann Liebert, Inc./Genetic Engineering News ...

"Alpha-1 Antitrypsin Deficiency Pipeline Insights"DelveInsight's,“Alpha1-Antitrypsin Deficiency (AATD) Pipeline Insight, 2025,” report provides comprehensive insights about 12+ companies and ...

The global alpha-1 antitrypsin deficiency (AATD) market is expanding, driven by advances in diagnosis, treatment, and growing awareness. Key players like Grifols, CSL Behring, and Pfizer lead ...

Augmentation Therapy for Severe Alpha-1 Antitrypsin Deficiency Improves Survival and Is Decoupled from Spirometric Decline – A Multi-National Registry Analysis. American Journal of Respiratory ...

This treatment is the only specific therapy for AATD and involves IV infusion of alpha-1 antitrypsin protein extracted from human donors. General treatment for COPD symptoms includes: short-acting ...

delivery and alpha-1 antitrypsin (AAT) expression within the respiratory tract following KB408 administration as well as safety and tolerability data for both KB407 and KB408 that, taken together ...